MARKET

CORV

CORV

Correvio Pharma Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3950
+0.0050
+1.28%
After Hours: 0.4100 +0.015 +3.80% 17:36 12/13 EST
OPEN
0.4000
PREV CLOSE
0.3900
HIGH
0.4000
LOW
0.3711
VOLUME
6.29M
TURNOVER
--
52 WEEK HIGH
4.440
52 WEEK LOW
0.3711
MARKET CAP
19.96M
P/E (TTM)
-0.4388
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CORV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CORV News

  • The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
  • Benzinga.9h ago
  • The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
  • Benzinga.9h ago
  • CORREVIO PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Correvio Pharma Corp. and Encourages Investors to Contact the Firm
  • Business Wire.22h ago
  • IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  • Business Wire.1d ago

More

Industry

Pharmaceuticals
+0.14%
Pharmaceuticals & Medical Research
-0.08%

Hot Stocks

Name
Price
%Change

About CORV

Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
More

Webull offers Correvio Pharma Corp (CORV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.